771 related articles for article (PubMed ID: 17177581)
1. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
Simpson KN; Jones WJ; Rajagopalan R; Dietz B
Clin Drug Investig; 2007; 27(12):807-17. PubMed ID: 18020538
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
Simpson KN; Jones WJ; Rajagopalan R; Dietz B
Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
[TBL] [Abstract][Full Text] [Related]
4. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Broder MS; Chang EY; Bentley TG; Juday T; Uy J
J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
Simpson KN; Rajagopalan R; Dietz B
Adv Ther; 2009 Feb; 26(2):185-93. PubMed ID: 19219410
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden.
Thuresson PO; Heeg B; Lescrauwaet B; Sennfält K; Alaeus A; Neubauer A
Scand J Infect Dis; 2011 Apr; 43(4):304-12. PubMed ID: 21231811
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Markov model and discrete-event simulation techniques for HIV.
Simpson KN; Strassburger A; Jones WJ; Dietz B; Rajagopalan R
Pharmacoeconomics; 2009; 27(2):159-65. PubMed ID: 19254048
[TBL] [Abstract][Full Text] [Related]
10. [Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain].
Smets E; Brogan AJ; Hill A; Adriaenssen I; Sawyer AW; Domingo-Pedrol P; Gostkorzewicz J; Ledesma F
Enferm Infecc Microbiol Clin; 2013; 31(7):430-6. PubMed ID: 23260386
[TBL] [Abstract][Full Text] [Related]
11. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
[TBL] [Abstract][Full Text] [Related]
12. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
Brogan A; Mauskopf J; Talbird SE; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.
Foglia E; Bonfanti P; Rizzardini G; Bonizzoni E; Restelli U; Ricci E; Porazzi E; Scolari F; Croce D
PLoS One; 2013; 8(2):e57777. PubMed ID: 23460905
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.
Brogan AJ; Smets E; Mauskopf JA; Manuel SA; Adriaenssen I
Pharmacoeconomics; 2014 Sep; 32(9):903-17. PubMed ID: 24906477
[TBL] [Abstract][Full Text] [Related]
15. Atazanavir/ritonavir: a review of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
17. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
18. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.
Möller J; Desai K; Simpson K; Baran RW; Van de Steen O; Dietz B; Gooch K
J Med Econ; 2014 Apr; 17(4):250-8. PubMed ID: 24351091
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.
Simpson KN; Luo MP; Chumney E; Sun E; Brun S; Ashraf T
HIV Clin Trials; 2004; 5(5):294-304. PubMed ID: 15562370
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
Mauskopf J; Brogan A; Martin S; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():83-105. PubMed ID: 21182346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]